Benign Prostatic Hyperplasia Treatment Market Size, Share, and Trends 2025 to 2034

The global benign prostatic hyperplasia treatment market size is calculated at USD 13.18 billion in 2025 and is forecasted to reach around USD 21.46 billion by 2034, accelerating at a CAGR of 5.56% from 2025 to 2034. The North America market size surpassed USD 4.37billion in 2024 and is expanding at a CAGR of 5.72% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : July 2025  |  Report Code : 6337  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Benign Prostatic Hyperplasia Treatment Market 

5.1. COVID-19 Landscape: Benign Prostatic Hyperplasia Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Benign Prostatic Hyperplasia Treatment Market, By Treatment Type

8.1. Benign Prostatic Hyperplasia Treatment Market Revenue and Volume Forecast, by Treatment Type

8.1.1. Pharmacological treatment

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Surgical treatment

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Minimally invasive procedures

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Other treatments

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Benign Prostatic Hyperplasia Treatment Market, By End Use

9.1. Benign Prostatic Hyperplasia Treatment Market Revenue and Volume Forecast, by End Use

9.1.1. Hospitals

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Clinics

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Ambulatory surgical centres

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Specialty urology centers

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Benign Prostatic Hyperplasia Treatment Market, By Patient Age Group

10.1. Benign Prostatic Hyperplasia Treatment Market Revenue and Volume Forecast, by Patient Age Group

10.1.1. Below 50 years

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. 50–60 years

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Above 60 years

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel 

11.1. Benign Prostatic Hyperplasia Treatment Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Hospital pharmacy          

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail pharmacy

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online pharmacy

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Benign Prostatic Hyperplasia Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Treatment Type

12.1.2. Market Revenue and Volume Forecast, by End Use

12.1.3. Market Revenue and Volume Forecast, by Patient Age Group

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.1.5.2. Market Revenue and Volume Forecast, by End Use

12.1.5.3. Market Revenue and Volume Forecast, by Patient Age Group

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.1.6.2. Market Revenue and Volume Forecast, by End Use

12.1.6.3. Market Revenue and Volume Forecast, by Patient Age Group

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.2. Market Revenue and Volume Forecast, by End Use

12.2.3. Market Revenue and Volume Forecast, by Patient Age Group

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.5.2. Market Revenue and Volume Forecast, by End Use

12.2.5.3. Market Revenue and Volume Forecast, by Patient Age Group

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.6.2. Market Revenue and Volume Forecast, by End Use

12.2.6.3. Market Revenue and Volume Forecast, by Patient Age Group

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.7.2. Market Revenue and Volume Forecast, by End Use

12.2.7.3. Market Revenue and Volume Forecast, by Patient Age Group

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.8.2. Market Revenue and Volume Forecast, by End Use

12.2.8.3. Market Revenue and Volume Forecast, by Patient Age Group

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.2. Market Revenue and Volume Forecast, by End Use

12.3.3. Market Revenue and Volume Forecast, by Patient Age Group

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.5.2. Market Revenue and Volume Forecast, by End Use

12.3.5.3. Market Revenue and Volume Forecast, by Patient Age Group

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.6.2. Market Revenue and Volume Forecast, by End Use

12.3.6.3. Market Revenue and Volume Forecast, by Patient Age Group

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.7.2. Market Revenue and Volume Forecast, by End Use

12.3.7.3. Market Revenue and Volume Forecast, by Patient Age Group

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.8.2. Market Revenue and Volume Forecast, by End Use

12.3.8.3. Market Revenue and Volume Forecast, by Patient Age Group

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.2. Market Revenue and Volume Forecast, by End Use

12.4.3. Market Revenue and Volume Forecast, by Patient Age Group

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.5.2. Market Revenue and Volume Forecast, by End Use

12.4.5.3. Market Revenue and Volume Forecast, by Patient Age Group

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.6.2. Market Revenue and Volume Forecast, by End Use

12.4.6.3. Market Revenue and Volume Forecast, by Patient Age Group

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.7.2. Market Revenue and Volume Forecast, by End Use

12.4.7.3. Market Revenue and Volume Forecast, by Patient Age Group

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.8.2. Market Revenue and Volume Forecast, by End Use

12.4.8.3. Market Revenue and Volume Forecast, by Patient Age Group

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.5.2. Market Revenue and Volume Forecast, by End Use

12.5.3. Market Revenue and Volume Forecast, by Patient Age Group

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.5.5.2. Market Revenue and Volume Forecast, by End Use

12.5.5.3. Market Revenue and Volume Forecast, by Patient Age Group

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.5.6.2. Market Revenue and Volume Forecast, by End Use

12.5.6.3. Market Revenue and Volume Forecast, by Patient Age Group

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. AbbVie Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Astellas Pharma Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. C.R. Bard, Inc. (BD)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Olympus Corporation

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Santarus, Inc. (Bausch Health Companies)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. UroGen Pharma Ltd.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Sonacare Medical LLC

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Stryker Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Richard Wolf GmbH

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global benign prostatic hyperplasia treatment market is expected to increase from USD 21.46 billion in 2024 to USD 12.49 billion by 2034.

The benign prostatic hyperplasia treatment market is expected to grow at a compound annual growth rate (CAGR) of around 5.56% from 2025 to 2034.

The major players in the benign prostatic hyperplasia treatment market include AbbVie Inc., Astellas Pharma Inc., Pfizer Inc., GSK (GlaxoSmithKline plc), Bayer AG, Boehringer Ingelheim GmbH, Mylan N.V. (Viatris), Ferring Pharmaceuticals, C.R. Bard, Inc. (BD), Olympus Corporation, Teleflex Incorporated, Boston Scientific Corporation, Santarus, Inc. (Bausch Health Companies), Medi-Tech International Inc., UroGen Pharma Ltd., Sonacare Medical LLC, Nobel Biocare Services AG, and Stryker Corporation.

The driving factors of the benign prostatic hyperplasia treatment market are the public awareness and improved healthcare access are leading to earlier BPH diagnosis and treatment, driving market growth by increasing patient willingness to seek effective care.

North America region will lead the global benign prostatic hyperplasia treatment market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client